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OBJECTIVE—The hypothalamic neuropeptide orexin inﬂu-
ences (feeding) behavior as well as energy metabolism. Admin-
istration of exogenous orexin-A into the brain has been shown to
increase both food intake and blood glucose levels. In the present
study, we investigated the role of endogenous hypothalamic
orexin release in glucose homeostasis in rats.
RESEARCH DESIGN AND METHODS—We investigated the
effects of the hypothalamic orexin system on basal endogenous
glucose production (EGP) as well as on hepatic and peripheral
insulin sensitivity by changing orexinergic activity in the hypo-
thalamus combined with hepatic sympathetic or parasympathetic
denervation, two-step hyperinsulinemic-euglycemic clamps, immu-
nohistochemistry, and RT-PCR studies.
RESULTS—Hypothalamic disinhibition of neuronal activity by
the -aminobutyric acid receptor antagonist bicuculline (BIC)
increased basal EGP, especially when BIC was administered in
the perifornical area where orexin-containing neurons but not
melanocortin-concentrating hormone–containing neurons were
activated. The increased BIC-induced EGP was largely prevented
by intracerebroventricular pretreatment with the orexin-1
receptor antagonist. Intracerebroventricular administration of
orexin-A itself caused an increase in plasma glucose and pre-
vented the daytime decrease of EGP. The stimulatory effect of
intracerebroventricular orexin-A on EGP was prevented by he-
patic sympathetic denervation. Plasma insulin clamped at two or
six times the basal levels did not counteract the stimulatory
effect of perifornical BIC on EGP, indicating hepatic insulin
resistance. RT-PCR showed that stimulation of orexin neurons
increased the expression of hepatic glucoregulatory enzymes.
CONCLUSIONS—Hypothalamic orexin plays an important role
in EGP, most likely by changing the hypothalamic output to the
autonomic nervous system. Disturbance of this pathway may
result in unbalanced glucose homeostasis. Diabetes 58:1998–
2005, 2009
T
he hypothalamic neuropeptide orexin is involved
in arousal and energy homeostasis (1). Lack of
orexin results in narcolepsy and hypophagia.
Despite the reduced food intake, both narcolep-
tic patients with orexin deﬁciency and the animal model
with genetic ablation of orexin neurons tend to be obese
(2,3). These ﬁndings indicate that the link between orexin
and energy homeostasis is not only via appetite stimula-
tion (4,5) but also involves additional mechanisms in the
control of energy metabolism. In keeping with this notion,
orexin-ataxin-3 transgenic mice show reduced metabolic
rate, independent of other behavioral changes induced by
orexin, such as arousal, locomotion, and food intake (6).
Orexin-A can regulate plasma glucose concentrations
via both central and peripheral mechanisms (7,8), but the
neurotransmitter(s) responsible for controlling the endog-
enous activity of the orexin neurons is (are) not evident.
Besides the glutamatergic input that is derived from a local
neuronal network (9), orexin neurons also receive -ami-
nobutyric acid (GABA)ergic inputs from a variety of brain
areas such as arcuate nucleus (ARC) neuropeptide Y
neurons (9), basal forebrain (10), and preoptic area (11).
During the light period (i.e., the sleeping/fasting period
of rats), orexin neurons in the perifornical area are in-
hibited by GABA inputs originating from the biological
clock neurons located in the suprachiasmatic nucleus
(SCN) (12). Interestingly, hypothalamic application of the
GABA receptor antagonist bicuculline (BIC) not only
activates orexin neurons (13) but also increases plasma
glucose concentrations (14–16).
To test the hypothesis that GABA acts as an inhibitory
neurotransmitter in upstream brain areas to control the
glucoregulatory function of orexin, we activated the
orexin neurons in the perifornical orexin area (PF-Oa) of
rats by retrodialysis of GABA receptor antagonist and
investigated its effect on endogenous glucose production
(EGP), using the stable isotope technique. The effect of
BIC on hepatic and peripheral insulin sensitivity was
investigated by performing euglycemic clamps at two
different levels of hyperinsulinemia. The speciﬁc involve-
ment of orexin neurons in the response of EGP to BIC was
conﬁrmed in several ways: 1) by comparing the EGP
response from BIC administration in the PF-Oa with that
in two nearby brain areas that do not contain orexin
neurons (i.e., the dorsal part of the dorsomedial hypothal-
amus [dDMH] and the hypothalamic paraventricular nu-
cleus [PVN]), 2) by comparing EGP responses with and
without intracerebroventricular coinfusion of orexin-1 re-
ceptor (OX-1R) antagonist SB-408124 during BIC adminis-
tration in the PF-Oa, and 3) by investigating the effects of
intracerebroventricular administration of orexin-A and
melanin-concentrating hormone (MCH) on EGP. To inves-
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1998 DIABETES, VOL. 58, SEPTEMBER 2009tigate the possible involvement of the autonomic nervous
system in the glucoregulatory actions of orexin-A, we
combined the intracerebroventricular administration of
orexin-A with speciﬁc hepatic sympathetic or parasympa-
thetic denervations. Furthermore, to elucidate the meta-
bolic signaling pathway utilized by the orexin system to
control hepatic insulin sensitivity, we also examined sev-
eral hepatic glucoregulatory factors by quantitative real-
time PCR.
RESEARCH DESIGN AND METHODS
All experiments were conducted under the approval of the animal care
committee of the Royal Netherlands Academy of Arts and Sciences. Male
Wistar rats weighing 300–350 g (Harlan Nederland, Horst, the Netherlands)
were housed in individual cages (25  25  35 cm), with a 12/12-h light-dark
schedule (lights on at 0700 h). Food and water were available ad libitum,
unless stated otherwise.
Surgery preparation. Animals underwent surgeries according to the differ-
ent experimental designs under anesthesia, with 0.8 ml/kg i.m. Hypnorm
(Janssen, High Wycombe, Buckinghamshire, U.K.) and 0.4 ml/kg s.c. Dormi-
cum (Roche, Almere, the Netherlands).
Silicon catheters were inserted into the right jugular vein and left carotid
artery for intravenous infusions and blood sampling, respectively. With a
standard Kopf stereotaxic apparatus, bilateral microdialysis probes (14) were
placed into the PF-Oa, dDMH, and the PVN. Intracerebroventricular guiding
probes were placed into the lateral cerebral ventricle. All coordinates were
adapted from the atlas of Paxinos and Watson (17) (see the online appendix
data 1 and Table 1 [available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0385/DC1]). All catheters and probes were ﬁxed on top of
the head and secured with dental cement.
Hepatic sympathetic or parasympathetic branches were denervated ac-
cording to our previously published methods (14). The effectiveness of the
hepatic sympathetic denervation was checked by measurement of norepi-
nephrine content in the liver as described before (18). After recovery, animals
were connected to a multichannel ﬂuid-infusion swivel (Instech Laboratories,
Plymouth Meeting, PA) 1 day before the experiment for adaption. Food was
removed at the beginning of the light period to exclude intestinal glucose
absorption. The ﬁrst experimental blood samples were collected 5 h later.
Tracer dilution study. To study glucose kinetics, [6,6-
2H2]glucose (as a
primed [8.0 mol in 5 min]-continuous [16.6 mol/h] infusion) was used as
tracer (99% enriched; Cambridge Isotopes, Andover, MA). In experiments
1–4, blood samples were taken at t  5 min for measuring background
enrichment of [6,6-
2H2]glucose, at t  90, 95, and 100 min for determining
enrichment during the equilibration state, and at t  210, 220, 230, 240, and 250
min for determining enrichment during the retrodialysis and/or intracerebro-
ventricular infusion of different drugs according to the different experimental
designs.
In experiment 1, Ringer’s dialysis (vehicle, 3 l/min) was started together
with [6,6-
2H2]glucose infusion in both BIC and vehicle groups. After the t 
100 min blood sample, the Ringer’s solution was changed to a BIC solution
(100 mol/l, 3 l/min; Sigma) or Ringer’s (vehicle control, 3 l/min) again.
After t  250 min blood sampling, to validate the placement of the microdi-
alysis probes, animals were perfused by 4% paraformaldehyde and went
through Nissl and immunohistochemical staining.
In experiment 2, the primed-continuous [6,6-
2H2]glucose infusion and
Ringer’s dialysis (vehicle) were started (after primary background blood
sampling) together with OX-1R antagonist 1-(6,8-diﬂuoro-2-methyl-quinolin-4-
yl)-3-(4-dimethylamino-phenyl)-urea (SB-408124) (50 mmol/l, 5 l/h; Sigma-
Aldrich, St. Louis, MO) or 20% DMSO (vehicle, 5 l/h); the dose of SB-408124
was adapted from SB-334867 in previously reported data (19,20). At the end of
the equilibration state, BIC retrodialysis was applied in both groups. After the
t  250 min sampling, animals were perfused and intracerebroventricular and
microdialysis probe placements were validated as described above.
In experiment 3, with liver nerve–intact rats, and in experiment 4, with liver
sympathetic–, parasympathetic–, or sham-denervated rats, after the t  100
min blood sample, a continuous intracerebroventricular infusion of orexin-A
(1 mmol/l, 5 l/h; Bachem, Weil am Rhein, Germany), MCH (1 mmol/l, 5 l/h;
Bachem) (only in experiment 3), or puriﬁed water (Milli-Q water, vehicle, 5
l/h) (only in experiment 3) (21) was started. After t  250 min blood
sampling, animals were then deeply anesthetized and 2 l colored dye was
injected via the intracerebroventricular guiding probe to validate the probe
placement.
In experiment 5, both hyperinsulinemic clamp 1 and clamp 2 consisted of
a basal Ringer’s (vehicle) equilibration period (t  0–100 min), a primary
Ringer’s (hyperinsulinemic-euglycemic clamp) period (t  110–140 min), and
a secondary BIC (hyperinsulinemic-euglycemic clamp) period (t  140–250
min). At t  100 min, insulin was administered in a primed (7.2 mU  kg
1 
min
1 in 4 min for clamp 1 and 21.6 mU  kg
1  min
1 in 4 min for clamp
2)-continuous (3 mU  kg
1  min
1 for clamp 1 and 9 mU  kg
1  min
1 for
clamp 2) intravenous infusion. A variable infusion of a 25% glucose solution
(containing 1% [6,6-
2H2]glucose) was used to maintain euglycemia (5.5  0.2
mmol/l), as determined by a 10-min carotid catheter blood sampling. Thirty
minutes after the start of the primary insulin infusion, Ringer’s perfusion of
the microdialysis probes was replaced by the BIC solution in BIC group. At the
end of the clamp, ﬁve blood samples were taken with a 10-min interval from
t  210–250 min. Liver tissue was then collected under deep anesthesia for
real-time PCR study, and animals were perfused for Nissl and immunohisto-
chemical staining.
Immunohistochemistry. For immunohistochemical staining, animals were
killed by an intra-atrial perfusion with saline, followed by a solution of 4%
paraformaldehyde in 0.1 mol/l phosphate buffer (pH 7.4) at 4°C. After
postﬁxation and equilibration for 48 h with 30% sucrose in 0.1 mol/l Tris-
buffered saline, the brain tissue was cut into 30-m sections and divided into
three equal groups for Fos and orexin or MCH immunostaining (online
appendix data 2).
Quantitative real-time PCR. Total RNA from liver tissue was isolated with
Trizol (Invitrogen), and single-stranded complementary DNA was synthesized.
One microliter of each cDNA was incubated in a ﬁnal volume of 20 l real-time
PCR containing 1  SYBR Green master mix (Applied Biosystems) and 3 pmol
reverse and 3 pmol forward primers (online appendix data 3 and Table 2).
Efﬁciency of primer was determined on the basis of a cDNA dilution series.
Quantitative real-time PCR was performed in an Applied Biosystems Prism
Sequence Detection System (model ABI7300). Standard PCR conditions were
used. The data were acquired and processed automatically by Sequence
Detection Software 33 (Applied Biosystems).
Analytical methods. Blood samples were immediately chilled on ice in tubes
containing a 5 l heparin solution and centrifuged at 4°C. Plasma was then
stored at 20°C for analysis. Plasma glucose concentrations were determined
using a glucose/glucose oxidase-perid method (Boehringer Mannheim, Mann-
heim, Germany). Plasma insulin, glucagon, and corticosterone concentrations
were measured using radioimmunoassay kits (Linco Research, St. Charles,
MO, and ICN Biomedicals, Costa Mesa, CA, respectively). Plasma [6,6-
2H2]glucose
enrichment was measured by gas chromatography–mass spectrometry.
Statistics. Results are expressed by averaging values from three plasma
samples at the end of the equilibration state and ﬁve plasma samples at the
end of the experimental period. Student’s t test was used to test orexin-A or
BIC effects on EGP, comparing the mean of the equilibration state with the
mean of the experimental period. ANOVA and post hoc Student’s t tests were
also performed to evaluate the BIC effects of different hypothalamic nuclei
and to compare the different states of (hyper)insulinemia.
RESULTS
Removal of the endogenous GABA inhibition of peri-
fornical orexin neurons stimulates EGP (experiment
1). Experiment 1 was performed to investigate whether
activation of orexin neurons during the light period would
affect glucose metabolism. Histological analysis of the
probe placements showed that the tip of the microdialysis
probes was located either in the lateral part of the PVN
(Fig. 1A2), at the upper borders of the PF-Oa (Fig. 1A3), or
in the dDMH (Fig. 1A4).
Rats with Ringer’s retrodialysis (n  6, vehicle) showed
no changes in plasma glucose levels as compared with
their own equilibration state (Fig. 1B); however, it showed
a clear decline in EGP (Fig. 1C). This steady decline most
likely is due to absence of food in the cages and not to the
different brain infusions, as it was not observed in animals
that remained in ad libitum conditions (online appendix
data 4, online appendix Fig. 1). Retrodialysis of BIC in the
PF-Oa (n  5) caused a signiﬁcant hyperglycemic re-
sponse and a pronounced increase in EGP as compared
with its own equilibration state as well as to that of the
Ringer’s infusion. Retrodialysis of BIC into the dDMH (n 
6) and PVN (n  4) also caused a signiﬁcant, albeit
smaller, hyperglycemic response. Different from the PF-Oa
group, both the dDMH and PVN group did not show a
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equilibration, but both groups differed signiﬁcantly from
the Ringer’s group at the end of their BIC administration
period. Plasma insulin levels were not affected by the BIC
treatment (Fig. 1D). In addition BIC, but not Ringer’s,
signiﬁcantly increased plasma corticosterone levels, with-
out signiﬁcant differences among the three groups (Fig.
1E). Moreover, no correlation was found between the area
under the curve of the corticosterone response and the
EGP increase in BIC-treated rats (r  0.55, P  0.10).
Immunohistochemical staining with the Fos antibody
showed that in BIC-treated brains (n  4–6), the major
part of the activated neurons (as indicated by the expres-
sion of Fos in their nucleus) was limited to a restricted
area around the dialysis probes (500 m spread from the
edge of the dialysis probe). Double immunohistochemical
stainings with Fos and orexin (n  4–6) showed that
when the Ringer’s dialysis probes ended in the upper part
of the PF-Oa, very few Fos positive nuclei (one to ﬁve per
section) were observed and no colocalization of orexin
and Fos was found. On the other hand, in animals with BIC
dialysis probes ending in the upper part of the PF-Oa,
double immunohistochemical staining showed that most
of the orexin neurons (81  14 single-labeled neurons per
section) were activated (58  9 Fos/orexin double-labeled
per section [i.e., 	71%]) (Fig. 2A). With the same BIC
stimulation, most of the MCH neurons that are inter-
spersed among the orexin neurons were not activated
(Fig. 2C). However, when dialysis probes were placed in
the dDMH, only a few orexin neurons (104  6 single-
labeled neurons per section) were activated (21  2
Fos/orexin double-labeled neurons per section [i.e.,
	20%]) (Fig. 2B)( P 
 0.001 vs. PF-Oa group). Fos
expression after BIC administration into the PVN did not
engage the orexin neurons. This speciﬁc activation of
orexin neurons by BIC is consistent with a previous study
that targeted BIC to the perifornical area (13). In addi-
tion, when most of the orexin neurons were Fos positive,
Fos immunoreactivity was also found in orexin-targeting
areas, such as PVN (Fig. 2E), locus coeruleus (Fig. 2G),
central amygdaloid nucleus (Fig. 2I), and even as far as
the intermediolateral cell column of the sacral spinal
cord (Fig. 2K) (22), conﬁrming the intensive activation of
orexin neurons. Although the ARC has been suggested to
be involved in the appetite-stimulating actions of orexin
(23,24), BIC administration into the PF-Oa did not result in
different numbers of Fos immunoreactive neurons in this
nucleus as compared with the Ringer’s control group
(6.6  1.5 vs. 3.3  0.5 per section, P  0.14).
Antagonizing the central orexin-1 receptor prevents
the increase in EGP induced by BIC administration in
the PF-Oa (experiment 2). Retrodialysis of BIC in the
PF-Oa, combined with intracerebroventricular vehicle
treatment, signiﬁcantly increased EGP (Fig. 1F) as well as
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FIG. 1. GABAa receptor antagonist BIC administration in the PVN, dDMH, or PF-Oa causes different EGP responses that are independent of
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corticosterone concentration before (equilibration state) and after BIC (or vehicle) in different hypothalamic nuclei. , vehicle retrodialysis
equilibration state; f, BIC (or vehicle) retrodialysis state. F: Average EGP before () and after a 2-h infusion of BIC in the PF-Oa (f) with
intracerebroventricular vehicle or orexin-1 receptor antagonist SB-408124 (pre)treatment. Intracerebroventricular (pre)treatment with the
SB-408124 blocks the BIC-induced EGP increase. C: Compact zone of DMH. DM, dorsomedial DMH; f, fornix; OT, optic tract; VL, ventrolateral
DMH; III, third ventricle; IV, fourth ventricle. Scale bar: 400 m. Data are presented as means  SE. #P < 0.05 vs. equilibration state; *P < 0.05
vs. vehicle control; ^P < 0.05 vs. dDMH and PVN.
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mmol/l, P 
 0.001) (i.e., similar to the results of experi-
ment 1). However, intracerebroventricular (pre)treatment
with SB-408124 prevented the BIC-induced increase in
EGP. The BIC-induced increase in plasma glucose concen-
tration was also attenuated, but it was still signiﬁcantly
higher than its own equilibration state (5.9  0.1 vs. 6.9 
0.2 mmol/l, P  0.002) and showed a trend to be signiﬁ-
cantly different from the BIC-induced increase in plasma
glucose in the vehicle group (P  0.055).
Central administration of orexin-A stimulates EGP
(experiment 3). To conﬁrm that orexin neurons are
indeed involved in the BIC-induced increase in EGP, in
experiment 3 we performed an intracerebroventricular
infusion of either orexin-A or vehicle. Intracerebroventric-
ular administration of vehicle had no effect on plasma
glucose levels (Fig. 3A). However, a clear decline in EGP
(Fig. 3B) and metabolic clearance rate (MCR) (EGP/
plasma glucose concentration) (Fig. 3C) was apparent
(i.e., similar to what was found in the Ringer’s animals of
experiment 1). Intracerebroventricular infusion of
orexin-A increased the plasma glucose level. In contrast to
the vehicle group, no decrease in EGP and MCR was
observed. EGP at the end of the orexin-A infusion was also
signiﬁcantly higher than that in the vehicle group at the
end of the infusion state; thus, intracerebroventricular
orexin-A prevented the endogenous decline of EGP.
Plasma insulin concentrations did not change during in-
tracerebroventricular infusion of either vehicle or
orexin-A (Fig. 3D). In line with the absence of Fos immu-
noreactivity in MCH neurons after BIC stimulation, no
signiﬁcant effects of intracerebroventricular-administered
MCH (n  5) on plasma glucose levels, EGP, or MCR
compared with the vehicle control animals were found
(Fig. 3A–C).
Hepatic sympathetic, but not parasympathetic, dener-
vation blocks the effect of intracerebroventricular
orexin-A infusion on EGP (experiment 4). Successful
hepatic sympathetic denervation (HSX) was validated by a
signiﬁcant decrease of liver norepinephrine concentra-
tions compared with sham denervation (shamX) (Fig. 3E).
After HSX, intracerebroventricular infusion of orexin-A no
longer could prevent the endogenous decline of EGP and
MCR as shown in experiment 3 (compare Fig. 3G and H
with Fig. 3B and C). However, after hepatic parasympa-
thetic denervation (HPX) or shamX the intracerebroven-
tricular infusion of orexin-A was as effective as in liver-
intact animals to prevent the endogenous drop in EGP and
MCR (Fig. 3G and H). Plasma glucose changes, on the
other hand, were not affected by any of the denervation
procedures (i.e., plasma glucose levels increased after
intracerebroventricular orexin-A infusion in all three
groups [Fig. 3F]). No differences were found in plasma
glucagon concentrations as a result of the intracerebro-
ventricular orexin-A infusion or the denervation procedure
(Fig. 3I).
Removal of the endogenous GABA inhibition of peri-
fornical orexin neurons reduces hepatic insulin sen-
sitivity (experiment 5). During clamp 1 (3 mU  kg
1 
min
1), retrodialysis of BIC in the PF-Oa (n  6) and
dDMH (n  4) after the equilibration state still induced a
signiﬁcant increase in EGP in both groups, despite the
presence of peripheral hyperinsulinemia (Fig. 4A). Fur-
thermore, EGP in the dDMH group was signiﬁcantly lower
f f
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FIG. 2. A–D: Fos immunoreactivity around the microdialysis probes in the PF-Oa and dDMH area. Fos and orexin double stainings are shown for
BIC administration in the PF-Oa (A) and dDMH (B). C: Fos and MCH double staining after BIC administration in the PF-Oa. D: Illustrates the
Fos and orexin double staining in a Ringer’s control. After BIC administration in the PF-Oa, Fos immunoreactivity is also present in orexin target
areas such as PVN (E), locus coeruleus (G), central amygdaloid nucleus (I), and intermediolateral cell column of the sacral spinal cord (K). F,
H, J, and L: The panels on their respective right side show the absence of Fos-ir in these areas with Ringer’s dialysis in PF-Oa area. E–L: Double
stained for Fos and orexin. The photos shown are representative for all the other animals in the same group, which are four to six rats depending
on individual groups. Cc, central canal; f, fornix; III, third ventricle; IV, fourth ventricle; OT, optic tract. Scale bar: A–D, G, and H: 100 m. E, F,
I–L: 200 m. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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suppression of EGP (i.e., hepatic insulin sensitivity) was
signiﬁcantly attenuated in both BIC groups compared with
their vehicle control groups (Fig. 4B), but the effect was
signiﬁcantly more pronounced in the PF-Oa group than in
the dDMH group. The rate of glucose disappearance (Rd)
was signiﬁcantly increased by BIC in the PF-Oa group but
not in the dDMH group (Fig. 4C) compared with their
respective control groups.
To explore the effect of BIC on peripheral insulin
sensitivity, clamp 2 with a higher plasma insulin level was
performed. Despite the higher insulin levels, which re-
sulted in a signiﬁcant further decrease in EGP in the two
Ringer’s control groups, BIC still caused a signiﬁcant
increase in EGP in both the PF-Oa (n  7) and the dDMH
(n  4) group compared with their respective control
groups (Fig. 4A). Again, the effect was more pronounced in
the PF-Oa group than in the dDMH group. With regard to
Rd, the two Ringer’s groups showed a signiﬁcantly higher
Rd, as compared with clamp 1, and both BIC groups
showed a signiﬁcantly higher Rd than the control groups
(Fig. 4C).
The real-time PCR study on the liver tissue revealed that
BIC treatment signiﬁcantly diminished the inhibitory effect
of hyperinsulinemia on the expression of phosphoenol-
pyruvate cerboxykinase (PEPCK) and glucose-6-phospha-
tase (G6Pase), as well as its stimulatory effect on the
expression of glucokinase (Fig. 5A–C). In addition to these
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have previously been associated with the development of
hepatic insulin resistance (25). However, the BIC-induced
activation of orexin neurons had no signiﬁcant effects on
the expression level of either tumor necrosis factor-
(TNF), interleukin-6 (IL-6), or suppressor of cytokine
signaling (SOCS)-3 (Fig. 5D–F).
DISCUSSION
Plasma glucose concentrations are kept within a narrow
physiological range by dynamically balancing glucose pro-
duction and utilization to avoid hypoglycemia and hyper-
glycemia and to guarantee substrate availability for energy
production. Disturbances in the regulation of glucose
metabolism can result in insulin resistance and type 2
diabetes. Accumulated animal data of recent years indi-
cate that derangements of hypothalamic neural networks
may act as a critical factor responsible for an unbalanced
glucose metabolism (26). The present study identiﬁes
orexin as one of the critical players in such a glucoregu-
latory hypothalamic network. Activation of orexin neu-
rons in the hypothalamic perifornical area increases
blood glucose concentrations via a stimulation of EGP.
For the stimulatory effect of orexin on glucose production
to become apparent, an intact autonomic outﬂow from
brain to liver via the hepatic sympathetic innervation is
essential.
DMH and PVN have both been deﬁned as being part of
the endocrine and autonomic hypothalamic output net-
work, with the general concept that the PVN functions as
the hypothalamic integrating center for autonomic and
endocrine information and serves as the ﬁnal neuroendo-
crine and autonomic output nucleus from the hypothala-
mus (27), whereas the DMH has a more speciﬁc role in
controlling the stress response and circadian rhythms of
sleep (28). In comparison with the PVN, the separation
between DMH and PF-Oa is less obvious. The rat DMH is
a large complex nucleus, with its dorsomedial and ventro-
lateral parts divided by a compact central zone. Unlike the
PVN, the different divisions of the DMH do not show a
clear neurochemical separation. For instance, a large part
of the PF orexin neurons extends into the ventrolateral
DMH. In fact, in some (lesion) studies the DMH was
considered as one area, often including part of the PF-Oa
(29). In the present study, the glucoregulatory effects of
BIC markedly differed between PF-Oa, dDMH, and PVN
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uptake. Removal of the GABAergic inhibition clearly sep-
arated the PF-Oa, dDMH, and PVN.
Within the PF-Oa area, the distribution of orexin and
MCH neurons strongly overlaps, without any colocaliza-
tion. MCH and orexin both have been characterized as
orexigenic peptides (30), and both orexin and MCH neu-
rons receive GABAergic inputs (31), as well as being
sensitive to other metabolic inputs such as leptin (32),
NPY/agouti-related peptide, and proopiomelanocortin
(33,34). Nevertheless, our and other studies (13) show that
during the sleep period only orexin, but not MCH, neurons
can be activated by removal of the GABAergic inhibition,
indicating that the stimulatory effect of BIC on EGP
probably involves activation of orexin, but not MCH,
neurons. Indeed, intracerebroventricular orexin, but not
intracerebroventricular MCH, was able to affect EGP, and
intracerebroventricular administration of the orexin antag-
onist blocked a major part of the EGP stimulatory effect of
BIC. Together, these data indicate that in the PF-Oa area,
orexin neurons play a prominent role in the control of
EGP.
Both neuronal and hormonal factors have been consid-
ered to relay the orexin signal to the periphery. Central
administration of orexin can activate the hypothalamo-
pituitary-adrenal axis and consequently increase plasma
corticosterone levels (35). Corticosterone is able to stim-
ulate hepatic glucose production, but in the present study
EGP responses to BIC were site speciﬁc, whereas the
corticosterone responses were not, suggesting that corti-
costerone is not the major factor responsible for the
increase in EGP. In addition, also an altered pancreatic
release of glucagon does not seem to be the determining
factor. An alternative pathway for relaying orexin signal-
ing to the liver is via the autonomic nervous system.
Indeed, orexin can inﬂuence liver function via a multilevel
sympathetic output pathway (36). Previous studies (14,21)
have already shown that denervation of the sympathetic
input to the liver abolishes a hypothalamic induced in-
crease in EGP. Also in line with other studies (37,38), a
purely hormonal effect of orexin on EGP is therefore not
very likely. In the present study, we showed that central
administration of orexin-A can only affect EGP when an
intact sympathetic innervation of the liver is present,
indicating a stimulatory effect of central orexin on sympa-
thetic neuronal outﬂow. Remarkably, the sympathetic
denervation of the liver did not prevent the stimulatory
effect of intracerebroventricular orexin-A on plasma glu-
cose concentrations. The separation of the plasma glucose
and EGP responses indicates that increased central orexin
signaling might affect plasma glucose concentrations not
only through changes in the hepatic glucose production
but also by affecting peripheral glucose uptake. A central
control of peripheral glucose uptake, mediated by the
autonomic nervous system, is also supported by previous
studies showing that the increased glucose uptake in
skeletal muscle and brown adipose tissue after the central
administration of N-methyl-D-aspartate and leptin is abol-
ished by sympathetic denervation (39,40). Since plasma
insulin is not affected by orexin-A administration and
hepatic sympathetic denervation (14), and our experi-
ments were performed under fasting condition, the effect
on glucose in experiment 4 seems to be mediated by a
change in non–insulin-dependent glucose uptake.
The GABAergic input to the orexin neurons is timed by
the central biological clock located in the SCN, with the
most prominent inhibition occurring during the sleep
period (13,41). This timed GABA input probably is respon-
sible for switching the orexin activity on and off in its
target areas, thereby controlling the sleep/wake cycle
(42,43). Since the SCN not only times glucose metabolism
(44) but also controls sympathetic preautonomic neurons
(45), very possibly the SCN utilizes GABA as a timing
signal to control orexin activity and consequently inﬂu-
ence sympathetic outﬂow and regulate glucose metabo-
lism. On the other hand, it is well accepted that insulin
signaling in the arcuate AGRP/NPY neurons accounts for
	40% of the insulin-mediated suppression of EGP via the
autonomic output to liver (21,46,47). Therefore, it is pos-
sible that removal of GABA inhibition at the level of the
PF-Oa could also block central insulin signaling by antag-
onizing the arcuate NPY/GABA projection to the orexin
neurons or by activating the orexinergic projection to the
arcuate NPY neurons (counteracting the suppressive ef-
fect of insulin on NPY neurons) (21,23,48). However, most
of our experiments were performed under basal insulin
conditions, making the contribution of such a pathway
less prominent. Nevertheless, the present data support the
conclusion from other studies using the orexin knockout
mice model by showing that orexin is indeed an essential
factor for maintaining hypothalamic insulin sensitivity for
glucose metabolism (49). However, at which hypothalamic
area and under which situation this interaction takes place
needs further investigation.
In conclusion, we identiﬁed orexin as an important
hypothalamic regulator of glucose homeostasis. The hypo-
thalamic orexin system is possibly involved in incorporat-
ing timing information from the master brain clock into
the control mechanism of EGP and also provides a possi-
ble molecular explanation for the previously observed
correlation between short sleep duration and an increased
risk for insulin resistance (50). The present results show
that the inappropriate activation of orexin neurons during
sleep deprivation will induce an increase in basal EGP and
a reduction in hepatic insulin sensitivity.
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